Sanofi: Stifel nudges up TP
(CercleFinance.com) - Stifel maintains its Buy rating on Sanofi shares, with a target price raised from E109 to E111.
The broker reports that attention will increasingly focus on FY 2025 and beyond, when growth is expected to be in double digits.
If the pipeline starts to deliver results, then the investment case would be for a very attractive turnaround story, the analyst believes.
We are reasonably optimistic that tolebrutinib with GEMINI and/or HERCULES will be successful by early September, which would be a major catalyst. This is why we have decided to make Sanofi our top pick among large-cap pharmaceutical companies for the third quarter, Stifel concludes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
The broker reports that attention will increasingly focus on FY 2025 and beyond, when growth is expected to be in double digits.
If the pipeline starts to deliver results, then the investment case would be for a very attractive turnaround story, the analyst believes.
We are reasonably optimistic that tolebrutinib with GEMINI and/or HERCULES will be successful by early September, which would be a major catalyst. This is why we have decided to make Sanofi our top pick among large-cap pharmaceutical companies for the third quarter, Stifel concludes.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.